Cardiff Oncology rugi bersih FY26 kuartal II menyempit menjadi USD 21,6 juta; revenue tetap USD 0,1 juta

Reuters2026/08/11 20:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cardiff Oncology melaporkan revenue kuartal II berakhir 30 Juni 2026 tetap di USD 0,1 juta.
Beban R&D anjlok 48,92% menjadi USD 5,92 juta, seiring lebih sedikit pasien dalam uji fase 2 mCRC.
Beban SG&A naik 14,65% menjadi USD 3,8 juta, terutama pada kenaikan biaya jasa profesional terkait sengketa IP dengan NMS.
Pendapatan bunga bersih turun 50% menjadi USD 0,4 juta, sementara kas yang dipakai untuk operasi membengkak menjadi USD 24,05 juta.
Kas, setara kas, investasi jangka pendek USD 34,5 juta; panduan likuiditas hingga kuartal III 2027, dengan “substantial doubt” atas going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-344545), on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cardiff Oncology rugi bersih FY26 kuartal II menyempit menjadi USD 21,6 juta; revenue tetap USD 0,1 juta

You may also like

Crypto prices